Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of human single-chain antibodies against SARS-associated coronavirus.

Intervirology - 1 Jan 2008

Leung K M, Feng D X, Lou Jianlong, Zhou Yu, Fung K P, Waye Mary M Y, Tsui Stephen K W, Chan Paul K S, Marks James D, Pang S F, Kan Y W

Abstract excerpt

The outbreak of severe acute respiratory syndrome (SARS), caused by a distinct coronavirus, in 2003 greatly threatened public health in China, Southeast Asia as well as North America. Over 1,000 patients died of the SARS virus, representing 10% of infected people. Like other coronaviruses, the SARS virus also utilizes a surface glycoprotein, namely the spike protein, to infect host cells. The spike protein of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asia, Southeastern

Share to Epitopes

Share to Neutralization Tests

Share to North America

Share to Peptide Library

Share to Severe acute respiratory syndrome-related coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 18724064
DOI: 10.1159/000151530
PMCID: PMC7179547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of human single-chain antibodies against SARS-associated coronavirus.PMID 18724064Read ↗

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potentialSemantic proximity Read ↗

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal modelsSemantic proximity Read ↗

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding DomainSemantic proximity Read ↗

Screening and Identification of Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific CTL EpitopesSemantic proximity Read ↗

Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variantsSemantic proximity Read ↗

Identification of Human Single-Domain Antibodies against SARS-CoV-2Semantic proximity Read ↗

Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly NeutralizingSemantic proximity Read ↗

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2Semantic proximity Read ↗

Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.Semantic proximity Read ↗

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsSemantic proximity Read ↗

Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding RegionSemantic proximity Read ↗

A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS‐CoV‐2 variants and wild‐type of the virusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.